Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.56 |
| ▸ | PPARG | P37231 | 14/20 | 0.56 |
| ▸ | PPARD | Q03181 | 6/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584675 | 0.89 | PPARA (0.53) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL3587800 | 0.87 | PPARA (0.52) | PPARAPPARGPPARD | |
| SCHEMBL5112238 | 0.83 | PPARG (0.76) | PPARAPPARGPPARDFFAR1PTPN2 | |
| SCHEMBL1435701 | 0.82 | PPARG (0.62) | PPARAPPARGPPARDFFAR1PTPN2 | |
| SCHEMBL5106224 | 0.81 | PPARA (0.85) | PPARAPPARGPPARD | |
| SCHEMBL4850282 | 0.80 | FFAR1 (0.56) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL7898762 | 0.80 | PPARG (0.62) | PPARAPPARGPPARDFFAR1PTPN2 | |
| SCHEMBL1435939 | 0.80 | PPARG (0.59) | PPARAPPARGPPARDFFAR1PTPN2 | |
| SCHEMBL6293714 | 0.78 | PPARG (0.64) | PPARAPPARGPPARDFFAR1PTPN2 | |
| SCHEMBL10367150 | 0.78 | PPARG (0.64) | PPARAPPARGPPARDFFAR1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1786790-B1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| EP-1786790-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006019833-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | PPARA 1387/4885PPARG 1272/4885PPARD 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.